- $168.05m
- $49.81m
- $138.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.57 | ||
| Price to Tang. Book | 1.22 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.21 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -36.49% | ||
| Return on Equity | -34.25% | ||
| Operating Margin | -90.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 110.56 | 105.52 | 122.37 | 137.42 | 138.9 | 170.89 | 187.66 | 9.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Quanterix Corporation is a life sciences company. The Company is focused on ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development proprietary digital Simoa detection technology enables customers to reliably detect protein biomarkers at ultra-low concentrations in blood, serum and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies. Its Simoa bead-based digital immunoassays utilize the basic principles of conventional bead-based sandwich ELISA. The HD-X is the Company's flagship instrument that empowers biomarker research and accelerates drug development. Its SR-X instrument is a compact benchtop instrument with a lower price point, more flexible assay preparation, and a wider range of applications. The Company's Spatial Biology solutions measure protein expression and cellular phenotypes within intact tissue while preserving spatial context and tissue architecture.
Directors
- E. Kevin Hrusovsky CHM (60)
- Michael Doyle CFO (64)
- Masoud Toloue CEX (41)
- David Duffy SVP (50)
- Dawn Mattoon SVP (48)
- Mark Roskey SVP (61)
- John Fry GCN (59)
- Shawn Stetson SDR (44)
- Martin Madaus LED (61)
- Keith Crandell IND (61)
- Sarah Hlavinka IND (56)
- Paul Meister IND (68)
- Laurie Olson IND (58)
- David Walt IND (68)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- April 25th, 2007
- Public Since
- December 7th, 2017
- No. of Shareholders
- 68
- No. of Employees
- 450
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 46,939,975
- Address
- 900 Middlesex Turnpike, BILLERICA, 01821
- Web
- https://www.quanterix.com/
- Phone
- +1 3026587581
- Auditors
- Ernst & Young LLP
Latest News for QTRX
Upcoming Events for QTRX
Q1 2026 Quanterix Corp Earnings Release
Quanterix Corp Annual Shareholders Meeting
Q2 2026 Quanterix Corp Earnings Release
Similar to QTRX
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anbio Biotechnology
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
FAQ
As of Today at 21:49 UTC, shares in Quanterix are trading at $3.58. This share price information is delayed by 15 minutes.
Shares in Quanterix last closed at $3.58 and the price had moved by -47.12% over the past 365 days. In terms of relative price strength the Quanterix share price has underperformed the S&P500 Index by -53.66% over the past year.
The overall consensus recommendation for Quanterix is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreQuanterix does not currently pay a dividend.
Quanterix does not currently pay a dividend.
Quanterix does not currently pay a dividend.
To buy shares in Quanterix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.58, shares in Quanterix had a market capitalisation of $168.05m.
Here are the trading details for Quanterix:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: QTRX
Based on an overall assessment of its quality, value and momentum Quanterix is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Quanterix is $7.50. That is 109.5% above the last closing price of $3.58.
Analysts covering Quanterix currently have a consensus Earnings Per Share (EPS) forecast of -$1.48 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quanterix. Over the past six months, its share price has underperformed the S&P500 Index by -27.85%.
As of the last closing price of $3.58, shares in Quanterix were trading -38.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quanterix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quanterix's management team is headed by:
- E. Kevin Hrusovsky - CHM
- Michael Doyle - CFO
- Masoud Toloue - CEX
- David Duffy - SVP
- Dawn Mattoon - SVP
- Mark Roskey - SVP
- John Fry - GCN
- Shawn Stetson - SDR
- Martin Madaus - LED
- Keith Crandell - IND
- Sarah Hlavinka - IND
- Paul Meister - IND
- Laurie Olson - IND
- David Walt - IND